"Contakt World: Truth in Health" Podcast Debuts on iHeartRadio - Episode 1 Features In-Depth Interview with Vaccine Expert Dr. Peter Hotez Entitled "Covid Kills, Vaccines Won't"

Listen Now Here

Tracker Ventures Corp. ("Tracker" or the "Company") (CSE:TKR)(OTC PINK:TLOOF)(FSE:B2I) today announced that Contakt LLC ("Contakt World"), a technology company modernizing public health and safety, has launched its previously announced podcast, "Contakt World: Trith in Health," through a production and distribution partnership with iHeartMedia. The podcast is available on iHeartRadio and other popular streaming sites for podcasts

"For our premiere episode, we're grateful Dr. Hotez took time out of his busy schedule to talk to us about vaccines, contact tracing, and the threats of misinformation - and appreciate Robert Ellington's informative session on kinship care, and the valuable work his organization HALOS is doing to help families struggling with the pandemic," said Justin Beck, CEO of Contakt World and host of the podcast.

A description of the first episode can be found below.

"Contakt World: Truth in Health" Podcast: Episode 1: Covid Kills, Vaccines Won't*

"What happens when a world-renowned scientist, vaccine expert and "OG Villain" (according to RFK Jr.) Dr. Peter Hotez, is allowed to speak his mind on issues surrounding a highly politicized and unprecedented pandemic? Join our hosts Justin Beck, Catherine Delcin and Deepti Pahwa as they explore the hot-button issues surrounding COVID-19 and other public health issues of our time. In this first episode of Contakt World, our hosts talk with Dr. Hotez, and explore his thoughts on the pandemic, as well as how it's affecting marginalized communities, driving misinformation and straining departments - and even how the biggest e-tailers can be leading promoters of anti-science attitudes. They also speak with Robert Ellington of HALOS - a nonprofit organization in Charleston, S.C., about kinship care, and how COVID has uprooted family structures of all kinds. So, tune in, listen up, and get informed."

"Contakt World: Truth in Health" is distributed by the iHeartPodcast Network.

*This statement, and all content within or related to this podcast, has not been evaluated by the FDA. Any information presented by Contakt World or its guests is not intended to treat or cure any disease, and no claims are made as to the accuracy or sufficiency thereof.

Contakt World - Tracker Transaction
Tracker and Contakt World are parties to a definitive amalgamation agreement pursuant to which Tracker will indirectly acquire (the "Acquisition") a 100% interest in Contakt World. For further information respecting the Acquisition, please refer to the Company's news release dated December 8, 2020. Trading of Tracker's shares on the Canadian Securities Exchange (the "CSE") has been halted in connection with the announcement of the Acquisition and is not expected to resume until the CSE has approved a Form 2A Listing Statement for the resulting issuer from the Acquisition. There can be no assurance that the Acquisition will be completed on the terms proposed in the amalgamation agreement or at all.

About Contakt World
Contakt World is a technology company innovating public health agency connections with their community, with the goal of becoming the most trustworthy, accessible and scalable digital public health and safety platform globally - addressing the needs of a post-pandemic world. Contakt World combines aggressive research and development, human-centered design, next-gen data integrations, and strategic health partnerships to empower and build mutual trust within communities, contributing towards health equity for users around the world. Contakt World's first suite of tools emerge from the urgency surrounding coronavirus to manage the pandemic through innovative contact tracing and case management spanning multiple modes of communication. For more information, please visit the Company's website at www.contakt.world.

Tracker Ventures Contact
Geoff Balderson
CEO and Director
Direct: 604-602-0001

Media Contact
Kevin Harrington
Account Director - 5WPR
contakt@5wpr.com

Investor Contact
Lucas A. Zimmerman
Senior Vice President - MZ North America
Direct: 949-259-4987
contakt@mzgroup.us
www.mzgroup.us

The CSE has not reviewed, approved or disapproved the content of this news release.

Forward-Looking Statements Disclaimer
This press release contains "forward-looking information" within the meaning of applicable securities laws ("forward-looking statements"), including, but not limited to, statements with respect to the future prospects of Tracker and Contakt World. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "projects", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements, including statements respecting the Partnership, the anticipated success thereof, the effect of the Partnership, podcast and future initiatives on trust and adoption of Contakt World's solutions and performance of the material terms of the Partnership. Although forward-looking statements contained in this press release are based upon what management of Tracker and Contakt World believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include those risks listed above as well as additional risks like regulatory changes, general economic, market, political, or business conditions, actual or perceived implications of COVID-19 immunization or treatments and the timing and delivery thereof, meeting or maintaining various conditions of HIPAA, GDPR, and CCPA compliance, protection of the Company's and Contakt World's intellectual property, and adoption of the Contakt World platform or apps by government, B2B, B2I customers and consumer end-users. Tracker and Contakt World undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

SOURCE: Tracker Ventures Corp.



View source version on accesswire.com:
https://www.accesswire.com/620296/Contakt-World-Truth-in-Health-Podcast-Debuts-on-iHeartRadio--Episode-1-Features-In-Depth-Interview-with-Vaccine-Expert-Dr-Peter-Hotez-Entitled-Covid-Kills-Vaccines-Wont

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×